The Use of Transdermal Buprenorphine to Relieve Radiotherapy-Related Pain in Head and Neck Cancer Patients.
Cancer Invest. 2013 Jun 11;
Authors: Menten J, Carpentier I, Deschutter H, Nuyts S, Van Beek K
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100 occurred in 26/45 patients 4 weeks after starting cancer therapy, persisting for ?2 weeks after treatment. These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 ?g/hr) where necessary to maintain pain scores ?30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day.
PMID: 23758187 [PubMed – as supplied by publisher]